{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:21:35Z","timestamp":1791566495294,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR077073-01A1"],"award-info":[{"award-number":["K23AR077073-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR078930-01A1"],"award-info":[{"award-number":["K23AR078930-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jaad.2023.01.014","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:37:06Z","timestamp":1674182226000},"page":"841-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease"],"prefix":"10.1016","volume":"88","author":[{"given":"Matthew T.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2023.01.014_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.014_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaad.2017.04.016","article-title":"Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: a retrospective analysis, 2004-2013","volume":"77","author":"Barbieri","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.014_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2018.4944","article-title":"Trends in oral antibiotic prescription in dermatology, 2008 to 2016","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2023.01.014_bib4","first-page":"752","article-title":"Isotretinoin, acne, and Crohn\u2019s disease: a convergence of bad skin, bad science, and bad litigation creates the perfect storm","volume":"9","year":"2013","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.014_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MEG.0000000000000496","article-title":"Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis","volume":"28","author":"Lee","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.014_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2020.07.041","article-title":"Isotretinoin and risk of inflammatory bowel disease: more data to support lack of meaningful risk","volume":"84","author":"Barbieri","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.014_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaad.2020.07.042","article-title":"Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin","volume":"84","author":"Wright","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.014_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2023.01.014_bib9","doi-asserted-by":"crossref","first-page":"100884","DOI":"10.1016\/j.eclinm.2021.100884","article-title":"Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses","volume":"36","author":"Agrawal","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.jaad.2023.01.014_bib10","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.014_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/jid.2014.290","article-title":"Propionibacterium acnes promotes Th17 and Th17\/Th1 responses in acne patients","volume":"135","author":"Kistowska","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2023.01.014_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8816041","article-title":"Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies","volume":"2021","author":"Zhao","year":"2021","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1016\/j.jaad.2023.01.014_bib13","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/ajg.2009.284","article-title":"Inflammatory bowel disease and acne","volume":"104","author":"Murphy","year":"2009","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"4","key":"10.1016\/j.jaad.2023.01.014_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.014_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaad.2020.07.075","article-title":"Validating the optimal classification approach using ICD-10 codes to identify dermatology patients with acne","volume":"84","author":"Barbieri","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2023.01.014_bib16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0000000000000915","article-title":"Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies","volume":"29","author":"Ortizo","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.014_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2022.04.050","article-title":"Genetic liability to acne is associated with increased risk of inflammatory bowel disease: a Mendelian randomization study","volume":"87","author":"Zhu","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.014_bib18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2017.07.842","article-title":"Phenotype and antimicrobial activity of Th17 cells induced by propionibacterium acnes strains associated with healthy and acne skin","volume":"138","author":"Agak","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.01.014_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjd.21704","article-title":"Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study","volume":"187","author":"Schneeweiss","year":"2022","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.014_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cgh.2015.09.013","article-title":"Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women","volume":"14","author":"Li","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.014_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaad.2022.05.024","article-title":"Impact of isotretinoin on IBD flare in patients with pre-existing IBD diagnosis: a cross-sectional study","volume":"87","author":"Lopez","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.014_bib22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments","volume":"80","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.01.014_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2015.09.046","article-title":"The use of oral antibiotics before isotretinoin therapy in patients with acne","volume":"74","author":"Nagler","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.01.014_bib24","first-page":"632","article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","volume":"17","author":"Barbieri","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.01.014_bib25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaad.2019.03.036","article-title":"Real-world drug usage survival of spironolactone versus oral antibiotics for the management of female patients with acne","volume":"81","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.01.014_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamadermatol.2019.3270","article-title":"Isotretinoin, patient safety, and patient-centered care-time to reform iPLEDGE","volume":"156","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:07:28Z","timestamp":1759273648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S019096222300083X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.01.014","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}